好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Long-term prognosis communication preferences in early-stage relapsing-remitting multiple sclerosis
Multiple Sclerosis
P17 - Poster Session 17 (11:45 AM-12:45 PM)
12-007

The aim of this study was to assess long-term prognosis (LTP) communication preferences and factors associated in early-stage relapsing-remitting multiple sclerosis (RRMS) patients.

Multiple sclerosis is one of the most common causes of neurological disability in young adults. Improving communication strategies on prognosis may help patients deal with the disease and adjust their life goals. However, there is limited information on patients’ preferences regarding the LTP communication.

 

A multicenter, non-interventional study was conducted. Adult patients with RRMS diagnosis, disease duration ≤3 years, and Expanded Disability Status Scale (EDSS) score of 0-5.5 were included. The Prognosis in MS questionnaire was used to assess how much patients want to know about their LTP. Patient-reported measures were administered to gather information on pain, fatigue, mood, anxiety, quality of life, stigma, feeling of hopelessness, and coping strategies. Cognition was assessed using the Symbol Digit Modalities Test (SDMT). A multivariate logistic regression analysis was performed to assess the association between LTP information preference and demographic, clinical characteristics, and patients’ perspectives.

A total of 189 patients were included (mean age: 36.1 ± 9.4 years, 71.4% female, mean disease duration: 1.2 ± 0.8 years). Median EDSS score was 1.0 (IQR=0.0-2.0). 68.5% (n=126/184) of patients had never discussed LTP with their neurologists, whereas 69.3% (n=126/182) reported interest in knowing about it (73.5% at diagnosis). Bivariate analyses suggested that patients were significantly more likely to have higher LTP information preferences if they were male and had a lower SDMT score, and a tendency was observed in those with lower perception of pain. Male gender and a lower SDMT score were predictors of LTP information preferences (OR=0.264; 95% CI: 0.09-0.64, p=0.006; OR=2.059; 95% CI: 1.02-4.32, p=0.049, respectively).

Patients with RRMS prefer to discuss LTP with their neurologists. Understanding factors involved may be useful to implement individualized communication strategies.

Authors/Disclosures
Tamara Castillo-Trivino, MD, MAS, FAAN (Donostia University Hospital)
PRESENTER
Dr. Castillo-Trivino has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biogen. Dr. Castillo-Trivino has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Merck. Dr. Castillo-Trivino has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis. Dr. Castillo-Trivino has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche. Dr. Castillo-Trivino has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sanofi. Dr. Castillo-Trivino has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Bristol-Myers Squibb. The institution of Dr. Castillo-Trivino has received research support from Basque Government.
Rocio Gomez Rocio Gomez has received personal compensation for serving as an employee of Roche Farma.
No disclosure on file
Jesus Manuel Martin Martinez Jesus Manuel Martin Martinez has nothing to disclose.
No disclosure on file
Ana M. Alonso Torres, MD Dr. Alonso Torres has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Janssen. Dr. Alonso Torres has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biogen. Dr. Alonso Torres has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis.
Ana Belen Caminero Rodriguez, MD (C/ Fuentes Claras #1) Dr. Caminero Rodriguez has nothing to disclose.
Laura Borrega Canelo Laura Borrega Canelo has received personal compensation in the range of $500-$4,999 for serving as a Consultant for BRISTOL. Laura Borrega Canelo has received personal compensation in the range of $500-$4,999 for serving as a Consultant for NOVARTIS. Laura Borrega Canelo has received personal compensation in the range of $500-$4,999 for serving as a Consultant for MERCK. Laura Borrega Canelo has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for BRISTOL. Laura Borrega Canelo has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for NOVARTIS. Laura Borrega Canelo has received research support from BRISTOL.
Jose Luis Sanchez Menoyo, MD (Neurologia - Hospital Galdakao-Usansolo) Dr. Sanchez Menoyo has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Merck. Dr. Sanchez Menoyo has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Sanofi. Dr. Sanchez Menoyo has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Merck. Dr. Sanchez Menoyo has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sanofi. Dr. Sanchez Menoyo has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis.
Francisco Barrero-Hernandez No disclosure on file
Carmen Calles, MD (Grupo 7 Viajes) Dr. Calles has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Sanofi, Biogen, Roche, Teva, Novartis, Merck. Dr. Calles has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sanofi, Teva, Biogen, Roche, Novartis, Merck.
Luis Brieva Ruiz, MD (Hospital Arnau Vilanova) Dr. Brieva Ruiz has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for All comercial companies interested in Multiple Sclerosis. Dr. Brieva Ruiz has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Al comercial companies in Multiple Sclerosis. The institution of Dr. Brieva Ruiz has received research support from Carlos III Institut. Madrid. Spain..
Rosario Blasco Quilez (Hospital Puerta De Hierro) Rosario Blasco Quilez has nothing to disclose.
Julio Dotor Garcia-Soto JULIO DOTOR GARCÍA-SOTO has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Merck . JULIO DOTOR GARCÍA-SOTO has received personal compensation in the range of $0-$499 for serving on a Speakers Bureau for Merck, Biogen, Sanofi-Genzyme, Almirall, Teva, UCB, Novartis.
Maria Campo Amigo Maria Campo Amigo has nothing to disclose.
Laura Navarro Laura Navarro has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche. Laura Navarro has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biogen idec. Laura Navarro has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sanofi-Genzyme.
Eduardo Aguera Morales, MD, PhD (As. ENINDE V14776132) Dr. Aguera Morales has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Merck. Dr. Aguera Morales has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis .
No disclosure on file
Olga Carmona Codina No disclosure on file
No disclosure on file
No disclosure on file
Mariona Hervas Pujol Mariona Hervas Pujol has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Sanofi, Merk, Bayer, Biogen, Almirall.
Jorge Maurino Jorge Maurino has received personal compensation for serving as an employee of Roche Pharma Spain, Medical Department.
No disclosure on file